Christian R. Geest

TL;DR: The data indicate that inhibition of BTK by PCI-32765 overcomes BCR- and chemokine-controlled integrin-mediated retention and homing of malignant B cells in their growth- and survival-supporting lymph node and bone marrow microenvironment, which results in clinically evident CLL regression.

TL;DR: A major clinical problem in chronic lymphocytic leukemia (CLL) is development of chemoresistance, which can be caused by genetic lesions but is also strongly influenced by the leukemic microenvironment.

TL;DR: The Noxa/Mcl-1 balance determines sensitivity to ABT-737 in CD40-stimulated CLL cells, and these data provide a rationale to investigate the combination of drugs which enhance the NoxA/M cl-1 Balance with ABT -737 to eradicate CLL in chemoresistant niches.

TL;DR: A novel role is identified in regulating the balance between proliferation and apoptosis during neutrophil differentiation, and the need for tight control of MEK-ERK activation is suggested to prevent the development of bone marrow failure.

TL;DR: It is shown that mTOR inhibition by rapamycin reduces the expansion of committed myeloid progenitors, but leaves the more primitive hematopoietic compartment unaffected, indicating that mammalian target ofRapamycin activity is essential for expansion of CD34+ hematopolietic progenitor cells during myelopoiesis.